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Introduction
Systemic onset juvenile idiopathic arthritis (SoJIA) shows
properties of autoinflammatory disease, and requires the
presence of arthritis and fever for diagnosis. The pro-
inflammatory proteins MRP8/14 (S100A8/9) and S100A12
are biomarkers which have been shown to detect ongoing
subclinical disease activity in patients with clinical remis-
sion. We compared the MRP8/14 (S100A8/9) and
S100A12 biomarker profile of patients in the AID-NET
(German Auto-inflammatory Disease Network) register to
further provide evidence for the usefulness of measure-
ment of these biomarkers.
Objectives
To characterize levels of pro-inflammatory markers of
innate immune activation, S100A12 and MRP8/14, during
active and inactive disease status of patients with SoJIA.
Methods
The AID-Net register, which includes patients with SoJIA
diagnosed according to ILAR criteria, was searched for
patients with clinically defined remission and flare epi-
sodes. Patients in remission were those documented as
being either: ‘non-acute’, in remission, or with a clinician
score of <1 (range 0-10, where 0 represents inactivity and
10 represent highly active disease). Flares were any cases
scored as ‘flare’ or ‘acute’. Statistical significance was
measured using the Mann-Whitney-U test, using SPSS.
Results
55 patients with a median age of 13 years (range 5-
20 years) at time of blood sampling were included. A
total of 158 episodes occurred where disease activity sta-
tus and MRP8/14 and S100A12 results were available.
This included 38 episodes of flares (19 patients) and 120
episodes of remission (44 patients). Patients presenting
with episodes of flare had significantly higher mean
S100A12 values compared with patients in remission
(mean 2,895 (range 15-19,410) ng/ml vs 575 (0-6,220)
ng/ml, respectively, p- < 0.01). MRP 8/14 values were
also higher in patients who were clinically flaring than
in those in remission (9,600 (100-48,610) ng/ml vs 2,965
(0-45,390) ng/ml, p < 0.01).
Conclusion
The measurement of MRP8/14 and S100A12 biomarkers
in patients with SoJIA in the AID-net register corre-
sponded well with the recorded clinical disease activity
in these patients. This provides further evidence for the
measurement of these biomarkers.
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